The Cambridge Analytica mess: What does it mean for pharma?
What happens in the world of Facebook cannot be ignored in pharma marketing. It increasingly lives in a world of data that is highly sensitive and must be managed well.
Data/Analytics
In [Insert Company Here] We Trust?
Whether it’s data or marketing dollars, there should be no surprises when you partner with a company.
Doctors who receive gifts from industry prescribe more branded drugs: study
In 2013, Medicare Part D prescribers who received a gift from a drugmaker prescribed 8% more brand-name drugs.
Study says drug development costs much less than previously estimated
New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
Shutterstock says men are ‘more responsive’ to online ads
Images that “mirror the demographic profile of their target audience” perform best, according to an eye-tracking study from picture provider Shutterstock.
Nearly every $100,000 drug approved in the last three years was for a rare disease
This includes Sarepta Therapeutics’ Exondys 5 and Vertex Pharmaceuticals’ Orkambi.
Infographic: The battle for medication adherence
Drugmakers and providers alike struggle to find the best tools, words, and technologies that will improve adherence rates among patients with chronic diseases.
Study: One-third of new drugs report safety issues
Drugs approved through the accelerated approval pathway, as well as psychiatric drugs, were more likely to have a safety issue following FDA approval.
U.S. drug spend grew by 6% in 2016, the lowest rate in two years
This is likely due to fewer product launches and lower price increases.
Day 2 at Health Datapalooza
The market for health data and technology is growing, but the industry must also address concerns about privacy, standards, and diversity.
Want to read more?
Please login or register first to view this content.
